

Lipocine to Present at The H.C. Wainwright 5th Annual NASH Investor Conference

SALT LAKE CITY, Oct. 5, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the H.C. Wainwright 5th Annual NASH Investor Conference being held virtually on October 12, 2021.

H.C. Wainwright 5th Annual NASH Investor Conference, October 12, 2021

Presentation time: 3:30 pm ET

Webcast link: <https://journey.ct.events/view/4e2b1d60-430e-4af3-8c5d-9f4ed7ad6012>

A webcast of Lipocine's presentation will be available on Lipocine's website under "Events & Presentations" in the Investors section or using the webcast link above. The webcast will be available on the Lipocine's website for 90 days.

About Lipocine

Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1107 and LPCN 1154. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a Phase 2 clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH. TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when administered as once daily or twice daily TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment of cirrhosis. LPCN 1154 is an oral neuro-steroid targeted for the treatment of post-partum depression. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. For more information, please visit www.lipocine.com.

SOURCE Lipocine Inc.

For further information: For further information: Morgan Brown, Executive Vice President & Chief Financial Officer, Phone: (801) 994-7383, mb@lipocine.com; Investors, Hans Vitzthum, Phone: (617) 535-7743, hans@lifesciadvisors.com

<https://ir.lipocine.com/2021-10-05-Lipocine-to-Present-at-The-H-C-Wainwright-5th-Annual-NASH-Investor-Conference>